NP41300: Dose Escalation Study of PD1-LAG3 Bispecific Antibody in Patients with Solid Tumours

• Research type

  Research Study

• Full title

  AN OPEN LABEL, MULTICENTER, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE SAFETY/TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND PRELIMINARY ANTI TUMOR ACTIVITY OF RO7247669, A PD1-LAG3 BISPECIFIC ANTIBODY, IN PATIENTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS

• IRAS ID

  1003440

• Contact name

  Fiona Thistlethwaite

• Contact email

  fiona.thistlethwaite@christie.nhs.uk

• Eudract number

  2019-000779-18

• REC name

  South Central - Oxford A Research Ethics Committee

• REC reference

  20/SC/0379

• Date of REC Opinion

  19 Jan 2021

• REC opinion

  Further Information Favourable Opinion